Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

CNTX has been the subject of a number of other research reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, November 6th. Jones Trading began coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target on the stock. HC Wainwright increased their price objective on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Context Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Context Therapeutics Trading Up 0.9%

Shares of NASDAQ CNTX opened at $2.28 on Friday. Context Therapeutics has a one year low of $0.49 and a one year high of $2.85. The business has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $1.18. The firm has a market capitalization of $209.49 million, a PE ratio of -9.50 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the third quarter valued at about $100,000. Vanguard Group Inc. increased its position in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the period. Finally, Clear Harbor Asset Management LLC increased its position in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.